7 results
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
(LTBI) Pathophysiology ... drug use • Silicosis ... Treatment: Active ... Initiating Treatment ... #Management #Treatment
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
(LTBI) Pathophysiology ... drug use • Silicosis ... Treatment: Active ... Initiating Treatment ... #Management #Treatment
IDSA - Clinical Strategy to Build an Individualized Treatment Regimen for Multi-Drug Resistant Tuberculosis (MDR-TB)
 •
Individualized Treatment ... Resistant Tuberculosis ... are contacts of infectious ... MDRTB #management #Treatment ... antimicrobials #regimens #pharmacology
Aimovig (Erenumab)
Mechanism: Calcitonin Gene-related Peptide Receptor Antagonist 
Indication: Preventive Treatment of Migraines:
Dosing: 70 mg SQ monthly,
Aimovig (Erenumab ... Indication: Preventive Treatment ... reported this drug ... Erenumab #Migraine #Neurology ... #Pharmacology #
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
Mycobacterium Tuberculosis ... Infection and Disease ... a person with infectious ... Mycobacterium #Tuberculosis ... #HIVAIDS #pharmacology
Transverse Myelitis Overview

Focal inflammatory disorder of the spinal cord resulting in rapid onset of weakness, sensory
monophasic Pathophysiology ... Pleocytosis > 100 cells ... , Hep A/B/CMV, TB ... Transverse Myelitis Treatment ... diagnosis #management #neurology
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
necessary based on drug-drug ... Note: Active TB ... IDSA #Prevention #Treatment ... opportunistic #infections ... #HIVAIDS #pharmacology